<![CDATA[Cretostimogene Grenadenorepvec Shows Complete Responses in NMIBC]]>

Phase 3positivecretostimogene grenadenorepvecPositive

AI Analysis

Summary

Final Phase 3 BOND-003 Cohort C results demonstrated a 75.5% complete response rate with cretostimogene grenadenorepvec in patients with BCG-unresponsive non-muscle invasive bladder cancer.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

75.5% complete response rate in BOND-003 Cohort C

Importance:7/10

Sentiment:

0.75

oncologybladder cancerNMIBCimmunotherapyPhase 3 data

Read the original article

Published by Cancer Network on July 28, 2026 5:00 PM

Read Original